These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15448374)

  • 1. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine.
    Pang H; Liu Y; Han X; Xu Y; Jiang F; Wu D; Kong X; Bartlam M; Rao Z
    J Gen Virol; 2004 Oct; 85(Pt 10):3109-3113. PubMed ID: 15448374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
    Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
    J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
    Suresh MR; Bhatnagar PK; Das D
    J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.
    Liu RY; Wu LZ; Huang BJ; Huang JL; Zhang YL; Ke ML; Wang JM; Tan WP; Zhang RH; Chen HK; Zeng YX; Huang W
    Virus Res; 2005 Sep; 112(1-2):24-31. PubMed ID: 16022898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
    Zhang CH; Guo ZM; Zheng HY; Lu JH; Wang YF; Yan XG; Zhao Y; DU XW; Zhang X; Fang L; Ling WH; Qi SY; Yu XB; Zhong NS
    Chin Med J (Engl); 2004 Nov; 117(11):1625-9. PubMed ID: 15569476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.
    Wang S; Chou TH; Sakhatskyy PV; Huang S; Lawrence JM; Cao H; Huang X; Lu S
    J Virol; 2005 Feb; 79(3):1906-10. PubMed ID: 15650214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
    Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
    Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
    Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
    Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine design for severe acute respiratory syndrome coronavirus.
    He Y; Jiang S
    Viral Immunol; 2005; 18(2):327-32. PubMed ID: 16035944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
    Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
    Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS corona virus peptides recognized by antibodies in the sera of convalescent cases.
    Guo JP; Petric M; Campbell W; McGeer PL
    Virology; 2004 Jul; 324(2):251-6. PubMed ID: 15207612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
    Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
    J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
    Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
    Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Chan C; He Y; Jiang S; Wu C; Jin DY; Yuen KY; Zhou Y; Zheng BJ
    Vaccine; 2008 Mar; 26(13):1644-51. PubMed ID: 18289745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.